Treatments for Scalp Psoriasis with Emphasis on Calcipotriol Plus Betamethasone Dipropionate Gel (Xamiol®)

Skin Therapy Letter-Family Practice Edition

关键词: calcipotriol;    betamethasone dipropionate;    steroid;    vitamin D analogue;    psoriasis;    scalp psoriasis;    fixed combinationtherapy;   

DOI  :  

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Scalp psoriasis occurs in 50%-75% of patients with plaque psoriasis. It may be the only area of the body affected, or it may beassociated with disease elsewhere, including psoriatic arthritis. Most cases are treated topically, usually with steroids and/orcalcipotriol. In 2008, Health Canada and the US FDA approved a stable, once-daily 2-compound gel containing calcipotriol andbetamethasone dipropionate (Xamiol®, LEO Pharma; Taclonex Scalp®, Warner Chilcott). This once-daily therapy improves patientquality of life with a quick onset of action and greater efficacy than monotherapy with either ingredient or twice daily treatment with calcipotriol 0.005% (Dovonex®, LEO Pharma) scalp solution. The gel vehicle was developed for ease of use, improved cosmeticacceptability and absorption on the scalp. By 2 weeks, approximately 60%, and by 8 weeks, approximately 70% of patients havecontrolled disease (i.e., absent or very mild disease). At 8 weeks, the calcipotriol and betamethasone dipropionate gel formulationhas a safety profile comparable with betamethasone dipropionate and is associated with significantly fewer adverse events thancalcipotriol. Xamiol® may be safely used for up to 52 weeks. No cases of atrophy, striae, or steroid purpura were noted in two52-week studies.

【 授权许可】

Unknown